Nicola A. Hanania @Hananianick · 2d, Nov 18, 2026, 8:48 PM The Lung Institute at Baylor College of Medicine@BCMLungInst Open video 2:32
Nicola A. Hanania @Hananianick · Oct 26, Oct 26, 2026, 12:41 PM healio.com/news/pulmonolo…@BCMLungInst @BCMDeptMedicine @BCM_Lung @CHESTAirways www.healio.com Systemic corticosteroid exposure drops with mepolizumab in COPD PHOENIX — Adults with COPD and an eosinophilic phenotype had lower exposure to systemic corticosteroids in a year with add-on mepolizumab vs. placebo, according to findings presented at the CHEST...
Nicola A. Hanania @Hananianick · Oct 17, Oct 17, 2026, 9:36 PM @BCMDeptMedicine @BCMLungInst @BCM_Lung bmjmedicine.bmj.com/content/5/1/e0… bmjmedicine.bmj.com Biological treatments for asthma and chronic obstructive pulmonary disease Asthma and chronic obstructive pulmonary disease (COPD) are highly prevalent heterogeneous airway diseases in which a subset of patients with severe disease have a disproportionate share of morbidity...
Nicola A. Hanania @Hananianick · Sep 24, Sep 24, 2026, 2:57 AM share.google/eS1DlsSl6iWQYv… www.hcplive.com Selecting a Biologic in Severe Asthma: Biomarkers, Comorbidities, and Payers | HCPLive With an anti-alarmin option that does not require a biomarker, selection could have become simpler. Dr. Hanania explains why it stays multifactorial, and why he waits before judging response.
Nicola A. Hanania @Hananianick · Sep 24, Sep 24, 2026, 2:54 AM share.google/vDQPekYCVpoW8u… www.ajmc.com Earlier Dupilumab Use Cuts Asthma Costs: Nicola Hanania, MD | AJMC Timely dupilumab initiation after a severe asthma exacerbation lowered costs vs delayed treatment, ERS 2026 data show.